Acute Respiratory Distress Syndrome – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Acute Respiratory Distress Syndrome – Pipeline Review, H1 2017’, provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome

The report reviews pipeline therapeutics for Acute Respiratory Distress Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acute Respiratory Distress Syndrome therapeutics and enlists all their major and minor projects

The report assesses Acute Respiratory Distress Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Altor BioScience Corp

Athersys Inc

Commence Bio Inc

Faron Pharmaceuticals Oy

GlaxoSmithKline Plc

Global Blood Therapeutics Inc

Hydra Biosciences Inc

Implicit Bioscience Ltd

Phylogica Ltd

Savara Inc

Silence Therapeutics Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Respiratory Distress Syndrome - Overview

Acute Respiratory Distress Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Respiratory Distress Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development

Altor BioScience Corp

Athersys Inc

Commence Bio Inc

Faron Pharmaceuticals Oy

GlaxoSmithKline Plc

Global Blood Therapeutics Inc

Hydra Biosciences Inc

Implicit Bioscience Ltd

Phylogica Ltd

Savara Inc

Silence Therapeutics Plc

Acute Respiratory Distress Syndrome - Drug Profiles

ALT-836 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-10901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-11006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GBT-440 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2586881 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2862277 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-067047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon beta-1a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit uPA for Acute Lung Injury,Acute Respiratory Distress Syndrome and Sepsis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit Endothelin-1 for Lung Cancer, Pulmonary Arterial Hypertension and Respiratory Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05285401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYC-35 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYC-36 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYC-38 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYC-98 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1229 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acute Respiratory Distress Syndrome - Dormant Projects

Acute Respiratory Distress Syndrome - Discontinued Products

Acute Respiratory Distress Syndrome - Product Development Milestones

Featured News & Press Releases

Oct 31, 2016: New Patent Application Accepted by Finnish Patent Office Protect the intravenous use of interferon-beta in a novel formulation

Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial

Sep 03, 2016: Queen’s University Developing New Drug against Leading Causes of Death in the UK - Sepsis and Ards

May 25, 2016: First patient dosed in Savaras pivotal trial for PAP

Mar 01, 2016: Faron files patent application to further strengthen protection for its novel Traumakine (FP-1201-lyo) formulation

Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS

Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome

Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP

Aug 09, 2015: Serendex to initiate first phase II clinical trial

Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November

May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced

May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical’s inhalable biological drug for treatment of severe pulmonary diseases

May 10, 2015: Positive topline data from Serendex phase I clinical trial

Feb 27, 2015: Serendex submits phase I application

Feb 13, 2015: Serendex partners up with leading German lung center

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Acute Respiratory Distress Syndrome – Pipeline by Altor BioScience Corp, H1 2017

Acute Respiratory Distress Syndrome – Pipeline by Athersys Inc, H1 2017

Acute Respiratory Distress Syndrome – Pipeline by Commence Bio Inc, H1 2017

Acute Respiratory Distress Syndrome – Pipeline by Faron Pharmaceuticals Oy, H1 2017

Acute Respiratory Distress Syndrome – Pipeline by GlaxoSmithKline Plc, H1 2017

Acute Respiratory Distress Syndrome – Pipeline by Global Blood Therapeutics Inc, H1 2017

Acute Respiratory Distress Syndrome – Pipeline by Hydra Biosciences Inc, H1 2017

Acute Respiratory Distress Syndrome – Pipeline by Implicit Bioscience Ltd, H1 2017

Acute Respiratory Distress Syndrome – Pipeline by Phylogica Ltd, H1 2017

Acute Respiratory Distress Syndrome – Pipeline by Savara Inc, H1 2017

Acute Respiratory Distress Syndrome – Pipeline by Silence Therapeutics Plc, H1 2017

Acute Respiratory Distress Syndrome – Dormant Projects, H1 2017

Acute Respiratory Distress Syndrome – Dormant Projects, H1 2017 (Contd..1), H1 2017

Acute Respiratory Distress Syndrome – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports